2014
Genotype and risk of major bleeding during warfarin treatment
Kawai V, Cunningham A, Vear S, Van Driest S, Oginni A, Xu H, Jiang M, Li C, Denny J, Shaffer C, Bowton E, Gage B, Ray W, Roden D, Stein C. Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics 2014, 15: 1973-1983. PMID: 25521356, PMCID: PMC4304738, DOI: 10.2217/pgs.14.153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiological Specimen BanksCytochrome P-450 CYP2C9Cytochrome P-450 Enzyme SystemCytochrome P450 Family 4Dose-Response Relationship, DrugEthnicityFemaleGene FrequencyGenetic Association StudiesGenetic VariationGenotypeHemorrhageHumansMaleMiddle AgedRisk FactorsVitamin K Epoxide ReductasesWarfarin
2013
Characterization of Statin Dose Response in Electronic Medical Records
Wei W, Feng Q, Jiang L, Waitara M, Iwuchukwu O, Roden D, Jiang M, Xu H, Krauss R, Rotter J, Nickerson D, Davis R, Berg R, Peissig P, McCarty C, Wilke R, Denny J. Characterization of Statin Dose Response in Electronic Medical Records. Clinical Pharmacology & Therapeutics 2013, 95: 331-338. PMID: 24096969, PMCID: PMC3944214, DOI: 10.1038/clpt.2013.202.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsAllelesAtorvastatinCholesterol, LDLCohort StudiesDatabases, FactualDose-Response Relationship, DrugElectronic Health RecordsGenotypeHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemiasLipid MetabolismLipidsPhenotypePolymorphism, Single NucleotidePyrrolesRandomized Controlled Trials as TopicSimvastatin
2012
Predicting warfarin dosage in EuropeanAmericans and AfricanAmericans using DNA samples linked to an electronic health record
Ramirez A, Shi Y, Schildcrout J, Delaney J, Xu H, Oetjens M, Zuvich R, Basford M, Bowton E, Jiang M, Speltz P, Zink R, Cowan J, Pulley J, Ritchie M, Masys D, Roden D, Crawford D, Denny J. Predicting warfarin dosage in EuropeanAmericans and AfricanAmericans using DNA samples linked to an electronic health record. Pharmacogenomics 2012, 13: 407-418. PMID: 22329724, PMCID: PMC3361510, DOI: 10.2217/pgs.11.164.Peer-Reviewed Original ResearchAdultAgedAged, 80 and overAnticoagulantsAryl Hydrocarbon HydroxylasesBlack or African AmericanCalcium-Binding ProteinsCytochrome P-450 CYP2C9Cytochrome P-450 Enzyme SystemCytochrome P450 Family 4Dose-Response Relationship, DrugDrug Administration ScheduleElectronic Health RecordsFemaleHumansMaleMiddle AgedMixed Function OxygenasesPolymorphism, Single NucleotideSubstance-Related DisordersVitamin K Epoxide ReductasesWarfarinWhite PeopleThe use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients
Birdwell K, Grady B, Choi L, Xu H, Bian A, Denny J, Jiang M, Vranic G, Basford M, Cowan J, Richardson D, Robinson M, Ikizler T, Ritchie M, Stein C, Haas D. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenetics And Genomics 2012, 22: 32-42. PMID: 22108237, PMCID: PMC3237759, DOI: 10.1097/fpc.0b013e32834e1641.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Body WeightCytochrome P-450 CYP3ADatabases, Nucleic AcidDose-Response Relationship, DrugDrug MonitoringElectronic Health RecordsFemaleGenetic Association StudiesGenotypeHemoglobinsHumansImmunosuppressive AgentsKidney TransplantationLinkage DisequilibriumMaleMiddle AgedPolymorphism, Single NucleotidePregnane X ReceptorReceptors, SteroidTacrolimusConceptsTacrolimus dose requirementsKidney transplant recipientsDose requirementsElectronic medical recordsBlood concentrationsTransplant recipientsMedical recordsCYP3A5 rs776746Electronic medical record dataInterindividual pharmacokinetic variabilityTacrolimus blood concentrationsNarrow therapeutic indexDNA biobanksMedical record dataTherapeutic drug monitoringDrug-metabolizing enzymesKidney transplantationClinical factorsPrimary outcomeImmunosuppressive drugsPharmacokinetic variabilityTacrolimus clearanceClinical covariatesPharmacogenomic predictorsTherapeutic index